Key facts
- Notable investors include Regent Partners (Seoul).
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for MagicBullet Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for MagicBullet Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MagicBullet Therapeutics
Developer of targeted anticancer therapeutics designed to address life-threatening diseases with unmet medical needs. The company focuses on research and development of target protein degradation technologies and next-generation kinase inhibitors to create first-in-class oncology drugs, enabling advancement of precision cancer treatments through innovative drug discovery approaches.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2022
- Website
- magicbullettx.openhaja.com/
- Ownership
- Privately Held (backing)
MagicBullet Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MagicBullet Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MagicBullet Therapeutics in its N-PORT filings yet. We sweep new filings monthly.